AMDL Receives $261,600 From Directors' Exercise of Expiring Options
July 26 2007 - 11:04AM
PR Newswire (US)
TUSTIN, Calif., July 26 /PRNewswire-FirstCall/ -- AMDL, Inc.
(AMEX:ADL), headquartered in Tustin, California, with operations in
Shenzhen, Jiangxi and Jilin, China, through its wholly owned
subsidiary Jade Pharmaceutical Inc., is an international biopharma
company. AMDL together with Jade engages in the development,
manufacture and marketing of proprietary pharmaceutical and
diagnostic products. AMDL announced today that it anticipates
receiving approximately $261,600 from the conversion of expiring
options held by various Company directors. These selected directors
hold approximately 109,000 common stock options at a conversion
price of $2.40 per share. "We believe our Directors are reinforcing
their strong faith in the future of the Company," said Gary Dreher,
CEO. "This welcome additional paid-in capital will be used for
general working capital purposes and to further Jade
Pharmaceutical's current marketing efforts." About Jade: Jade has
access to the fastest growing pharmaceutical and consumer market in
the world: China. AMDL, through its subsidiaries, Jade currently
manufactures large volume injection fluids, tablets and other
related products, holding licenses for 133 products. It also
manufactures 107 generic, over the counter and supplemental
pharmaceutical products under certified Chinese Good Manufacturing
Practice (CGMP) standards. About AMDL: More information about AMDL
and its products is available at http://www.amdl.com/ .
Forward-Looking Statements: This news release contains
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Such statements are
subject to certain risks and uncertainties, and actual
circumstances, events or results may differ materially from those
projected in such forward-looking statements. The Company cautions
readers not to place undue reliance on any forward-looking
statements. The Company does not undertake, and specifically
disclaims any obligation, to update or revise such statements to
reflect new circumstances or unanticipated events as they occur.
Contact: AMDL, Inc. Mr. Paul Knopick AMDL Investor Relations Direct
Line: 949.707.5365 Voice Mail: 714.505.4460 DATASOURCE: AMDL, Inc.
CONTACT: Mr. Paul Knopick, AMDL Investor Relations, Direct Line,
+1-949- 707-5365, or Voice Mail, +1-714-505-4460 Web site:
http://www.amdl.com/
Copyright
Amdl (AMEX:ADL)
Historical Stock Chart
From Jun 2024 to Jul 2024
Amdl (AMEX:ADL)
Historical Stock Chart
From Jul 2023 to Jul 2024